Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing–remitting multiple sclerosis in The Netherlands

References

• Kurtzke J. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52
   PubMed Web of Science ®Google Scholar
• Nationaal Kompas Volksgezondheid RIVM. Cijfers multiple sclerose (prevalentie, incidentie en sterfte naar leeftijd en geslacht). 2010. www.nationaalkompas.nl. Accessed June 22, 2012
   Google Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life in multiple sclerosis in The Netherlands. HEPAC: health economics in prevention and care. Eur J Health Econ 2006;7(2 Suppl):S55-64
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006;77:918-26
   PubMed Web of Science ®Google Scholar
• Weinshenker B. The natural history of multiple sclerosis. Neurol Clin 1995;13:119-46
   PubMed Web of Science ®Google Scholar
• Naci H, Fleurence R, Birt J, et al. The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature. J Med Econ 2010;13:78-89
   PubMedGoogle Scholar
• College voor Zorgverzekeringen. Farmacotherapeutisch Kompas. 2011. www.fk.cvz.nl. Accessed June 22, 2012
   Google Scholar
• European Medicines Agency. Assessment report: Gilenya (EMEA/H/C/2202). European Medicines Agency, London, UK; 2011. p 1–117
   Google Scholar
• Novartis Europharm Limited. Summary of product characteristics Gilenya. Novartis Europharm Limited, Horsham, UK; 2011. p 1–17
   Google Scholar
• Elan Pharma International Ltd. Summary of product characteristics Tysabri. Elan Pharma International Ltd., Athlone, Ireland; 2006. p 1–36
   Google Scholar
• Kappos L, Radue E, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Eng J Med 2010;362:387-401
   PubMed Web of Science ®Google Scholar
• Polman C, O’Connor P, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Eng J Med 2006;354:899-910
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Eng J Med 2010;362:402-15
   PubMed Web of Science ®Google Scholar
• College voor Zorgverzekeringen. CFH rapport 12/02: fingolimod (Gilenya). College voor Zorgverzekeringen, Diemen, The Netherlands; 2012, p. 1–6
   Google Scholar
• TLV Tandvårds- och läkemedelsförmånsverket (Swedish Dental and Pharmaceutical Benefits Agency). Swedish TLV report fingolimod (Gilenya) 11/08. TLV, Täby, Sweden; 2011. p 1–4
   Google Scholar
• College voor Zorgverzekeringen. Handleiding voor kostenonderzoek: methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. 2010
   Google Scholar
• Centraal Bureau voor de Statistiek. CBS Statline. 2011. http://statline.cbs.nl. Accessed June 22, 2012
   Google Scholar
• Z-Index B.V. Z-Index, Taxe. 2011. http://www.z-index.nl/taxe. Accessed June 22, 2012
   Google Scholar
• Hospital protocol 2. Hospital protocol: Fingolimod (Gilenya), Anonymous, The Netherlands; 2011. p 1–4
   Google Scholar
• Hospital protocol 3. Hospital protocol: Fingolimod (Gilenya), Anonymous, The Netherlands; 2011. p 1–3
   Google Scholar
• Hospital protocol 4. Hospital protocol: Fingolimod (Gilenya), Anonymous, The Netherlands; 2011. p 1–5
   Google Scholar
• Hospital protocol 5. Hospital protocol: Natalizumab (Tysabri), Anonymous, The Netherlands; 2011. p 1–7
   Google Scholar
• Hospital protocol 6. Hospital protocol: Natalizumab (Tysabri), Anonymous, The Netherlands; 2011. p 1–3
   Google Scholar
• Nederlandse Zorgautoriteit. NZa Tariefapplicatie. 2011. http://dbc-tarieven.nza.nl/Nzatarieven. Accessed June 22, 2012
   Google Scholar
• Hospital protocol 1. Hospital protocol: Natalizumab (Tysabri), Anonymous, The Netherlands; 2006. p 1–7
   Google Scholar
• Association of British Neurologists. Revised (2009) Association of British Neurologists’ guidelines for prescribing in multiple sclerosis, ABN, London, UK; 2009. p. 1–5
   Google Scholar
• De Smet MD, Taylor SRJ, Bodaghi B, et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res 2011;30:452-70
   PubMed Web of Science ®Google Scholar
• Donker G, van der Haar E. Waterpokken: vaccinatie invoeren of niet? Huisarts en Wetenschap 2009;52:165
   Google Scholar
• Clifford DB, De Luca A, DeLuca A, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010;9:438-46
   PubMed Web of Science ®Google Scholar
• Del Santo F, Maratea D, Fadda V, et al. Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis. Eur J Clin Pharmacol 2012;68(4):441-8. Epub 2011 Nov 5
   PubMedGoogle Scholar
• Goodman A. Multiple sclerosis: treatment update. 2008:1–10. http://www.ucsfcme.com/2008/MNR08001/GoodmanMultipleSclerosisHighlights.pdf. Accessed June 22, 2012
   Google Scholar
• Hutchinson M, Kappos L, Calabresi PA, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 2009;256:405-15
   PubMed Web of Science ®Google Scholar
• Von Rosenstiel P, Hohlfeld R, Calabresi P, et al Clinical outcomes in subgroups of patients treated with fingolimod (FTY720) or placebo: 24-month results from FREEDOMS. In: 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. 16. Göteborg, Sweden; 2010, p 434
   Google Scholar
• O’Day K, Meyer K, Miller RM, et al. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. J Med Econ 2011;14:617-27
   PubMedGoogle Scholar
• European Medicines Agency. European Medicines Agency gives new advice to better manage risk of adverse effects on the heart with Gilenya. European Medicines Agency, London, UK; 2012. p 1–2
   Google Scholar
• College voor Zorgverzekeringen. Medicijnkosten.nl. 2011. www.medicijnkosten.nl. Accessed June 22, 2012
   Google Scholar